Education
About Us
Working with TipRanks
Follow Us
Azitra Inc (AZTR)
:AZTR
Top Page
Azitra Inc
(NYSE MKT:AZTR)
Rating:44Neutral
Price Target:―
Positive Factors
Clinical Trials
Focus remains on lead program ATR-12 in Netherton syndrome, which dosed the first patient in its P1b study, with initial data expected soon.
Regulatory Approvals
ATR-04 has fast track designation, indicating a streamlined development process to potentially bring the therapy to market sooner.
Negative Factors
Financial Performance
Factoring in dilution associated with the two recent financings lowers the 12-month price target to $2.00, from $3.00.
Azitra Inc (AZTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)821.40K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth-98.69%
EPS Growth87.57%
CountryUS
Employees12
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,226,355
10 Day Avg. Volume1,087,658
30 Day Avg. Volume821,396
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.40
Price to Sales (P/S)0.00
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.00Price Target Upside971.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Azitra Inc Business Overview & Revenue Model
Company DescriptionAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
How the Company Makes MoneyAzitra Inc generates revenue primarily through the development and commercialization of its microbiome-based therapeutics. The company leverages partnerships with pharmaceutical companies and research institutions to advance its product pipeline and bring therapies to market. Revenue streams include licensing agreements, milestone payments, and potential royalties from commercialized products. Additionally, Azitra may obtain funding through research grants and collaborations that support the development of its innovative treatments.
Azitra Inc Financial Statement Overview
Summary
Azitra Inc shows strong revenue growth, but faces high operating losses and negative cash flows. The balance sheet improvement is overshadowed by significant liabilities and cash constraints.Income Statement
Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.35
Negative
Balance Sheet
The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.45
Neutral
Cash Flow
Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.30
Negative
| Breakdown | |||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|
| Income Statement | Total Revenue | ||
| 7.50M | 686.00K | 284.00K | 110.00K | Gross Profit |
| 7.50M | 260.45K | -121.98K | 25.23K | EBIT |
| -10.99B | -7.62M | -9.45M | -9.22M | EBITDA |
| -10.99B | -10.67M | -10.02M | -8.79M | Net Income Common Stockholders |
| -8.97M | -11.28M | -10.68M | -8.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||
| 4.55M | 1.80M | 3.49M | 8.04M | Total Assets |
| 7.36M | 5.12M | 7.17M | 10.20M | Total Debt |
| 555.51M | 885.95K | 7.73M | 992.02K | Net Debt |
| -4.00M | -910.04K | 4.24M | -7.05M | Total Liabilities |
| 1.66M | 2.20M | 43.43M | 35.97M | Stockholders Equity |
| 5.70B | 2.91M | -36.26M | -25.77M |
| Cash Flow | Free Cash Flow | ||
| -10.56M | -7.68M | -8.51M | -8.52M | Operating Cash Flow |
| -10.22M | -7.36M | -8.35M | -8.07M | Investing Cash Flow |
| -379.25M | -318.26K | -336.76K | -652.27K | Financing Cash Flow |
| 13.36M | 5.98M | 4.13M | 992.86K |
Azitra Inc Technical Analysis
Negative
0.28
Price Trends
0.29
Negative
0.31
Negative
0.42
Negative
Market Momentum
>-0.01
Negative
47.68
Neutral
45.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.29, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.68 is Neutral, neither overbought nor oversold. The STOCH value of 45.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.
Azitra Inc Risk Analysis
Azitra Inc disclosed 44 risk factors in its most recent earnings report. Azitra Inc reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business. Q4, 2024
Azitra Inc Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
45 Neutral | $768.88K | ― | -89.21% | ― | -83.72% | 99.56% | |
45 Neutral | $3.24M | ― | -468.00% | ― | ― | 98.55% | |
44 Neutral | ― | -208.50% | ― | -98.69% | 87.57% | ||
30 Underperform | $1.54M | ― | -300.16% | ― | ― | 79.57% | |
29 Underperform | $3.57M | ― | -192.72% | ― | ― | 56.26% | |
27 Underperform | $3.14M | ― | -512.79% | ― | ― | -40.51% |
* Healthcare Sector Average
Performance Comparison
AZTR
Azitra Inc
0.28
-4.28
-93.86%
BDRX
Biodexa Pharmaceuticals
1.15
-23.35
-95.31%
SLRX
Salarius Pharmaceuticals
0.72
-2.62
-78.44%
PCSA
Processa Pharmaceuticals
0.32
-1.26
-79.75%
GRI
GRI Bio
1.38
-57.18
-97.64%
PTIX
Protagenic Therapeutics
3.64
-9.87
-73.06%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.